Enlivex Finalizes Prospectus for Resale of 23.3M Shares by Selling Shareholder
ENLV sits 23% above its 52-week low of $0.66.
Summary
Enlivex Ltd. filed a final prospectus enabling a selling shareholder to resell up to 23.3 million ordinary shares, representing a significant potential dilution without any proceeds to the company.
Key Events · Financing and Capital Events · ENLV
-
Resale of Shares Enabled
A selling shareholder, Lind Global Asset Management XIV, LLC, is now able to resell up to 23,333,333 ordinary shares.
-
No Company Proceeds
Enlivex Ltd. will not receive any proceeds from the sale of these shares, as they are being sold by the existing shareholder.
-
Source of Shares
The shares are issuable upon conversion of a Senior Secured Convertible Promissory Note, for which the selling shareholder paid $19.0 million for a $21.0 million principal amount on March 23, 2026.
-
Significant Market Overhang
The potential resale of these shares, valued at approximately $19.07 million based on the current stock price, creates a significant overhang on the stock, representing nearly 10% of the company's current market capitalization.
Analysis · ENLV · Life Sciences
This 424B3 filing finalizes the prospectus for the resale of a substantial block of shares by a selling shareholder, Lind Global Asset Management XIV, LLC. This follows the F-3 registration statement filed on April 21, 2026, which signaled the intent for this resale. While the company previously secured $19.0 million from the convertible note that is the source of these shares, the current filing enables the selling shareholder to convert and sell up to 23.3 million shares, valued at approximately $19.07 million based on the current stock price. This event is negative for existing shareholders as it represents significant potential dilution (nearly 10% of current market capitalization) without any direct capital infusion to the company. Investors should monitor the pace and pricing of these potential sales, as a large influx of shares could pressure the stock price.
At the time of this filing, ENLV was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $193.7M. The 52-week trading range was $0.66 to $2.10. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.